Get started
INmune Bio Inc.INmune Bio Inc.INmune Bio Inc.

INmune Bio Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

INMB trade ideas

XPro1595 Decreases Neuroinflammation in Patients with Alzheimer’INmune Bio, Inc. Announces Interim Phase Ib Data Demonstrating That XPro1595 Decreases Neuroinflammation in Patients with Alzheimer’s Disease XPro1595 reduces neuroinflammation by 40.6% in a brain fiber pathway important for learning and memory Interim results from a Phase Ib clinical trial show that treatment with XPro1595 decreases white matter free water, a biomarker of neuroinflammation measured by MRI The preliminary results from INmune Bio’s Phase Ib study add to the growing enthusiasm for tackling neuroinflammation in the treatment of Alzheimer’s disease. www.globenewswire.com
NASDAQ:INMB
by AlenCiken
INMB,our low-float Nasdaq listed Biotech alert, Zero Debt, $19PT===================== INmune Bio Inc. (INMB) Alert Price: $5.60 Float: 3.58M Corporate Presentation Must Watch Interview w/ CEO Raymond J. Tesi MD at Nasdaq. Fact Sheet 12-Month Consensus Price Target: $19.00 (Zacks Small-Cap Research) Website | Recent News ======================== Members, Before we get into our next great trade idea, we want to congratulate all of our members who acted on yesterday's trade alert, and secured the up to +42% in realistic gains it delivered over the past two days! We are keeping our pedal to the metal and releasing an even more exciting (and possibly more profitable) trade idea. Please turn your immediate attention to INmune Bio Inc. (INMB). INmune Bio, Inc. is a publicly traded (INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INMB could probably be the most attractive biotech company listed on the Nasdaq exchange that you've never heard of. But we don't believe that INMB will be flying under the radar for much longer. The Company's CEO Raymond J. Tesi MD was just interviewed at Nasdaq, and we loved what he had to say. Dr . Tesi highlighted the recent developments in INMBs programs for cancer, Alzheimer’s disease and nonalcoholic steatohepatitis (NASH) liver disease. He also discussed reaching new milestones in the development of therapies that target the innate immune system which we will cover in this report. Once you've listened to the interview, we think you'll agree that the future appears very bright for INMB, and that the best is yet to come. INMB: Harnessing the Power of the Innate Immune System INMBs therapies provide treatment for diseases that effect millions of patients each year. Alzheimer’s Disease – The Alzheimer’s disease therapeutics market will grow to be worth more than $12 billion annually by 2026. Cancer Residual Disease – About 1.7 million patients are affected by this every year, with nearly 610,000 patients dying as a result. Checkpoint Inhibitor Market – The global checkpoint inhibitor market will grow to be worth more than $40 billion annually by the year 2026. NASH - A progressive disease caused by excessive fat accumulation in the liver that induces chronic inflammation, resulting in fibrosis that can lead to cirrhosis, liver failure, cancer and death. By 2020, NASH is projected to become the leading cause of liver transplants in the U.S. No medications are currently approved for the treatment of the disease. About INmune Bio, Inc. INmune Bio, Inc. is a publicly traded (INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for cancer (INB03), Alzheimer’s (XPro595, and NASH (NeuLiv). The Innate Immune Priming Platform includes INKmune aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. IMmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com. Company Highlights: Public clinical stage immunology company In 2020 - 2 Phase II programs and 2 Phase I programs Efficient use of capital and funding sources to maximize run-way Opportunity to add clinical programs as resources become available Two product platforms targeting innate immune dysfunction Programs in cancer, AD and NASH Product platform technologies provide multiple strategic opportunities Experienced management team Multiple programs provide sum-of-parts value Upcoming Milestones for INMB 3Q19 – First patient enrolled XPro1595 AD trial 1H20 – initiate NeuLiv Phase II NASH cancer trial 1H20 – initiate INB03 combination Phase II cancer trial 2H20 – XPro1595 AD Phase I trial data 4Q20 – first patient enrolled (INKMUNE) cancer trial The Bullish Case for INMB Has Zero Debt Trades on the NASD exchange Has an extremely tight float (3.58M) Is trading well under analyst’s price targets, with plenty of room to the upside. (Zacks Small-Cap Research has a $19 PT for INMB, an upside of over +239% from today's alert price.) Has witnessed some heavy insider buying as of late. United States Patent and Trademark Office (USPTO) has given formal notice of allowance to Patent Application Serial No. 15/776,061, titled “CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR NECROSIS FACTOR”, Which covers (INKmune’s) INB03 Program utilizing dominant negative TNFA (DN-TNFA) technology for treating cancer. Is presenting at the upcoming Alzheimer’s Association International Conference (AAIC) Satellite Symposium held Sept. 25 – 27 in Sydney, Australia. Get to Know INMB Impressive Pipeline Inkmune Bio has four drug development programs: two that are designed to treat cancer, INKmune™ and INB03 — with recently reported positive preliminary data from the Phase 1 trial in patients with advanced cancer; XPro1595 for the treatment of neuroinflammation and Alzheimer’s disease; and NeuLiv™ for the treatment of NASH. Inkmune -Cancer - in oncology patients that relapse, cells that are known to target residual cancer cells, fail to eliminate the remainder of the disease after treatment. INMB is working to keep this from happening with INKmune. INB03-Alzheimers - targets myeloid derived suppressor cells, or MDSC, believed to be the reason that many cancer patients do not respond to checkpoint inhibitor treatments. XPro1595-Cancer – is under development as a potential option for patients with Alzheimer’s disease, believed to be caused by neuroinflammation of brain cells. The company believes XPro1595 will inhibit neuroinflammation and the resultant cell death. NeuLiv - May enable INMB to target the underlying cause of NASH, to help stop the disease and allow the liver to heal “NASH presents a significant unmet medical need. We believe NeuLiv™ may enable us to target the underlying cause of NASH, to help stop the disease and allow the liver to heal,” said RJ Tesi, M.D., Chief Executive Officer of INmune Bio. “NeuLiv precisely targets soluble TNF, a key cytokine driving pathologic chronic inflammation. Unlike treatments focused on addressing fibrosis directly, we believe NeuLiv™ targets peripheral, regional and local causes of innate immune dysfunction that lead to chronic inflammation in patients with NASH. We hope this strategy will prevent progression of the disease and allow hepatic repair mechanisms to function.” Innate immune dysregulation, also called chronic inflammation, is a low-grade inflammatory state that, over time, has detrimental effects on organs, including the liver and brain. NeuLiv™, which is the third drug development program originating from INmune Bio’s DN-TNF platform, is a next generation TNF inhibitor that neutralizes soluble TNF (sTNF) without affecting trans-membrane TNF (tmTNF) or TNF receptors. By targeting soluble TNF, NeuLiv may alter the complex immunobiology that causes the development and progression of NASH. NASH is a progressive disease caused by excessive fat accumulation in the liver that induces chronic inflammation, resulting in fibrosis that can lead to cirrhosis, liver failure, cancer and death. By 2020, NASH is projected to become the leading cause of liver transplants in the U.S. No medications are currently approved for the treatment of the disease. INMB's Pipeline's Multi-Billion Dollar Market Opportunity • NeuLiv – NASH market – Market size >$7B • XPro1595 - Alzheimer’s/dementia market* – 5.8 M patients in US – 2019 est cost to care for US AD patients $280B • INKmune - Cancer residual disease market ** – 1,735,350 new cases and 609,640 people will die – Initial targets: Ovarian Cancer and High Risk MDS • INB03 - Resistance to Checkpoint Inhibitors market*** – CPI’s work 27% of patients. CPI 2025 est market size $56B – INB03 in combination with CPI’s should increase the number of patients sensitive to CPIs. – Initial targets: Melanoma and Renal Cell Cancer Three of the candidates in the company’s pipeline are either currently in Phase 1 clinical studies or are about to begin Phase 1 clinical studies in the near term. INB03 Australia Solid Tumors Initial Phase 1 Data Readout- Q3 ’19 INKmune UK Ovarian Cancer Initiate Enrollment of Phase 1/2 study - Q4 ’19 INB03 Australia Solid Tumors Initiate Combination Study, Additional Cohorts to Phase 1 Study- 1H ’20 XPro1595 UK Alzheimer’s Initiate Enrollment of Phase 1 Study - Q3’19 INKmune UK Ovarian Cancer Report Initial Phase 1 Data - 1H ’20 XPro1595 UK Alzheimer’s Early Data - Q1’20 INKmune UK Ovarian Cancer Initiate Phase 2 Study - 2H ’20 INB03 Australia/US Solid Tumors Initiate INB03 + CPI* Phase 2 Combination Study - 1H ’20 The Alzheimer Association believes in INMB In order to advance XPro1595 in the treatment of AD, INmune was recently awarded a $1 million grant from the Alzheimer’s Association. The grant will support a biomarker-directed Phase 1 clinical trial in 18 patients with mild-to-moderate AD. XPro1595 will be administered subcutaneously once a week for three months and biomarkers of inflammation will be assessed at 0, 6, and 12 weeks. This ringing endorsement from the Alzheimer Association should have potential investors sold on INMB's potential to help treat this dreaded disease that effects 5.8M patients in the U.S. alone. The Smart Money Is Buying Up Shares In INMB Insiders own 63% of the outstanding shares of INMB. Insiders have spent $770,000 buying up company shares in the past two months. An institutional investor recently raised its position in INmune Bio stock. BlackRock Inc . boosted its stake in INmune Bio Inc (NASDAQ:INMB) by 1,556.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,048 shares of the company’s stock after acquiring an additional 2,864 shares during the period. BlackRock Inc .’s holdings in INmune Bio were worth $29,000 at the end of the most recent reporting period. 0.36% of the stock is owned by hedge funds and other institutional investors. Major shareholder Mark William Lowdell purchased 2,918 shares of INmune Bio stock in a transaction that occurred on Wednesday, September 11th. The stock was acquired at an average cost of $6.23 per share, with a total value of $18,179.14. The Company has zero debt! The fact that insiders own 63% of the shares, has us bullish on INMB's growth potential. Who would know better if the Company was undervalued than those working within? Tiny Float = Big Move Potential The public float for INMB is just 3.58M A float that low is a rarity for companies listed on the NASDAQ. It also means the IMNB could moonshot if it were to see an increase in daily volume . In fact, the first time INMB broke over 100K in daily volume , its shares had their biggest single day move, climbing from $8.80 to $10.68, for a single day gain of over +21%! INMB Trades At $5.60 And Has A $19 Price Target Zacks Small-Cap Research recently initiated coverage of INmune Bio, Inc. (NASDAQ:INMB) with a $19 valuation. INmune is a biopharmaceutical company developing therapies that target the innate immune system to treat cancer. In contrast to the adaptive immune system, which relies upon a highly targeted response to specific antigens, the innate immune system is designed to deliver a non-specific response to abnormal cells or foreign antigens. The company targets myeloid derived suppressor cells (MDSC) and natural killer ( NK ) cells through its lead development products, INB03 and INKmune. INB03 is designed to inhibit soluble tumor necrosis factor (sTNF), a key signaling molecule for MDSC activation while INKmune provides the necessary priming signal to convert NK cells from a ‘resting’ to an ‘active’ state. In addition to the two cancer therapies, INmune is also developing XPro1595 (which has a similar MOA as INB03) as a treatment for mild to moderate Alzheimer’s Disease. Upcoming catalysts for the company include: INB03 – A Phase 1 monotherapy trial is currently underway. This trial will transition to a combination therapy clinical trial in the summer of 2019. A Phase 2 clinical trial testing INB03 with checkpoint inhibitors in patients who are resistant to checkpoint inhibitor therapy will initiate in 2020. XPro1595 – We anticipate a Phase 1 clinical trial in patients with Alzheimer’s disease will initiate in the summer of 2019. This study is supported by a $1 million grant from the Alzheimer’s Association. INKmune – A Phase 1/2 clinical trial will initiate later in 2019 in patients with relapsed/refractory ovarian cancer. With an upside of over +239%, now could be the perfect time to start building a position in INMB. Recent Developments CEO of INmune Bio Inc. Discusses Company Accomplishments at Nasdaq’s MarketSite and Announces Presentation at World Immunotherapy Congress Yesterday, the Company announced that RJ Tesi, M.D., Co-Founder and CEO will be featured in an interview with multimedia financial reporter, Jason Lin discussing the company’s accomplishments. The interview can be found by clicking here. “Nasdaq’s MarketSite is a premiere platform for INmune Bio to share our story with investors and to discuss recent developments in our programs for cancer, Alzheimer’s disease and nonalcoholic steatohepatitis (NASH) liver disease,” said Dr . Tesi. “We hope to continue reaching new milestones in the development of therapies that target the innate immune system.” INmune Bio has four drug development programs: two that are designed to treat cancer, INKmune™ and INB03 — with recently reported positive preliminary data from the Phase 1 trial in patients with advanced cancer; XPro1595 for the treatment of neuroinflammation and Alzheimer’s disease; and NeuLiv™ for the treatment of NASH. Additionally, CJ Barnum, Ph .D., Director of Neuroscience, will present on “Approaching Alzheimer’s disease as an immunological disease: role of biomarkers” at the World Immunotherapy Congress on Oct. 16 in Switzerland Technical Analysis We've done our very own chart analysis on INMB, and see the potential for a move of over 60%! Bollinger Bands Have Tightened Signaling a Comprehensive Move Imminent Sell Volume Declining Very Strong Reversal of the Lows Bullish H&S Forming RSI in Oversold Territory The stock has seen multiple bounces and reversals throughout its short history, which leads us to believe that now may be the perfect entry point for those looking to capitalize on INMB's next potential chart reversal. The Bottom-Line We don't think INMB will be trading under the radar for much longer. We love the CEO's vision for the future. With its low-float, INMB could see a huge run-up on volume . ZERO Debt and Heavy Insider Ownership have us bullish heading into the 2nd half of 2019. (*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.) Best Regards, *Past performance is not an indicator of future returns. The publishers of this report are not investment advisors and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. The publishers of this report have received compensation from a third party of USD $10,000 cash for a 1-day marketing contract for INMB. Never make investment decisions based on anything the publisher of this report says. This message is meant for informational and educational purposes only and does not provide investment advice.
NASDAQ:INMBLong
by DEXWireNews
INMB,our low-float Nasdaq listed Biotech alert, Zero Debt, $19PT===================== INmune Bio Inc. (INMB) Alert Price: $5.60 Float: 3.58M Corporate Presentation Must Watch Interview w/ CEO Raymond J. Tesi MD at Nasdaq. Fact Sheet 12-Month Consensus Price Target: $19.00 (Zacks Small-Cap Research) Website | Recent News ======================== Members, Before we get into our next great trade idea, we want to congratulate all of our members who acted on yesterday's trade alert, and secured the up to +42% in realistic gains it delivered over the past two days! We are keeping our pedal to the metal and releasing an even more exciting (and possibly more profitable) trade idea. Please turn your immediate attention to INmune Bio Inc. (INMB). INmune Bio, Inc. is a publicly traded (INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INMB could probably be the most attractive biotech company listed on the Nasdaq exchange that you've never heard of. But we don't believe that INMB will be flying under the radar for much longer. The Company's CEO Raymond J. Tesi MD was just interviewed at Nasdaq, and we loved what he had to say. Dr. Tesi highlighted the recent developments in INMBs programs for cancer, Alzheimer’s disease and nonalcoholic steatohepatitis (NASH) liver disease. He also discussed reaching new milestones in the development of therapies that target the innate immune system which we will cover in this report. Once you've listened to the interview, we think you'll agree that the future appears very bright for INMB, and that the best is yet to come. INMB: Harnessing the Power of the Innate Immune System INMBs therapies provide treatment for diseases that effect millions of patients each year. Alzheimer’s Disease – The Alzheimer’s disease therapeutics market will grow to be worth more than $12 billion annually by 2026. Cancer Residual Disease – About 1.7 million patients are affected by this every year, with nearly 610,000 patients dying as a result. Checkpoint Inhibitor Market – The global checkpoint inhibitor market will grow to be worth more than $40 billion annually by the year 2026. NASH - A progressive disease caused by excessive fat accumulation in the liver that induces chronic inflammation, resulting in fibrosis that can lead to cirrhosis, liver failure, cancer and death. By 2020, NASH is projected to become the leading cause of liver transplants in the U.S. No medications are currently approved for the treatment of the disease. About INmune Bio, Inc. INmune Bio, Inc. is a publicly traded (INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for cancer (INB03), Alzheimer’s (XPro595, and NASH (NeuLiv). The Innate Immune Priming Platform includes INKmune aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. IMmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com. Company Highlights: Public clinical stage immunology company In 2020 - 2 Phase II programs and 2 Phase I programs Efficient use of capital and funding sources to maximize run-way Opportunity to add clinical programs as resources become available Two product platforms targeting innate immune dysfunction Programs in cancer, AD and NASH Product platform technologies provide multiple strategic opportunities Experienced management team Multiple programs provide sum-of-parts value Upcoming Milestones for INMB 3Q19 – First patient enrolled XPro1595 AD trial 1H20 – initiate NeuLiv Phase II NASH cancer trial 1H20 – initiate INB03 combination Phase II cancer trial 2H20 – XPro1595 AD Phase I trial data 4Q20 – first patient enrolled (INKMUNE) cancer trial The Bullish Case for INMB Has Zero Debt Trades on the NASD exchange Has an extremely tight float (3.58M) Is trading well under analyst’s price targets, with plenty of room to the upside. (Zacks Small-Cap Research has a $19 PT for INMB, an upside of over +239% from today's alert price.) Has witnessed some heavy insider buying as of late. United States Patent and Trademark Office (USPTO) has given formal notice of allowance to Patent Application Serial No. 15/776,061, titled “CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR NECROSIS FACTOR”, Which covers (INKmune’s) INB03 Program utilizing dominant negative TNFA (DN-TNFA) technology for treating cancer. Is presenting at the upcoming Alzheimer’s Association International Conference (AAIC) Satellite Symposium held Sept. 25 – 27 in Sydney, Australia. Get to Know INMB Impressive Pipeline Inkmune Bio has four drug development programs: two that are designed to treat cancer, INKmune™ and INB03 — with recently reported positive preliminary data from the Phase 1 trial in patients with advanced cancer; XPro1595 for the treatment of neuroinflammation and Alzheimer’s disease; and NeuLiv ™ for the treatment of NASH. Inkmune -Cancer - in oncology patients that relapse, cells that are known to target residual cancer cells, fail to eliminate the remainder of the disease after treatment. INMB is working to keep this from happening with INKmune. INB03-Alzheimers - targets myeloid derived suppressor cells, or MDSC, believed to be the reason that many cancer patients do not respond to checkpoint inhibitor treatments. XPro1595-Cancer – is under development as a potential option for patients with Alzheimer’s disease, believed to be caused by neuroinflammation of brain cells. The company believes XPro1595 will inhibit neuroinflammation and the resultant cell death. NeuLiv - May enable INMB to target the underlying cause of NASH, to help stop the disease and allow the liver to heal “NASH presents a significant unmet medical need. We believe NeuLiv™ may enable us to target the underlying cause of NASH, to help stop the disease and allow the liver to heal,” said RJ Tesi, M.D., Chief Executive Officer of INmune Bio. “NeuLiv precisely targets soluble TNF, a key cytokine driving pathologic chronic inflammation. Unlike treatments focused on addressing fibrosis directly, we believe NeuLiv™ targets peripheral, regional and local causes of innate immune dysfunction that lead to chronic inflammation in patients with NASH. We hope this strategy will prevent progression of the disease and allow hepatic repair mechanisms to function.” Innate immune dysregulation, also called chronic inflammation, is a low-grade inflammatory state that, over time, has detrimental effects on organs, including the liver and brain. NeuLiv™, which is the third drug development program originating from INmune Bio’s DN-TNF platform, is a next generation TNF inhibitor that neutralizes soluble TNF (sTNF) without affecting trans-membrane TNF (tmTNF) or TNF receptors. By targeting soluble TNF, NeuLiv may alter the complex immunobiology that causes the development and progression of NASH. NASH is a progressive disease caused by excessive fat accumulation in the liver that induces chronic inflammation, resulting in fibrosis that can lead to cirrhosis, liver failure, cancer and death. By 2020, NASH is projected to become the leading cause of liver transplants in the U.S. No medications are currently approved for the treatment of the disease. INMB's Pipeline's Multi-Billion Dollar Market Opportunity • NeuLiv – NASH market – Market size >$7B • XPro1595 - Alzheimer’s/dementia market* – 5.8 M patients in US – 2019 est cost to care for US AD patients $280B • INKmune - Cancer residual disease market ** – 1,735,350 new cases and 609,640 people will die – Initial targets: Ovarian Cancer and High Risk MDS • INB03 - Resistance to Checkpoint Inhibitors market*** – CPI’s work 27% of patients. CPI 2025 est market size $56B – INB03 in combination with CPI’s should increase the number of patients sensitive to CPIs. – Initial targets: Melanoma and Renal Cell Cancer Three of the candidates in the company’s pipeline are either currently in Phase 1 clinical studies or are about to begin Phase 1 clinical studies in the near term. INB03 Australia Solid Tumors Initial Phase 1 Data Readout- Q3 ’19 INKmune UK Ovarian Cancer Initiate Enrollment of Phase 1/2 study - Q4 ’19 INB03 Australia Solid Tumors Initiate Combination Study, Additional Cohorts to Phase 1 Study- 1H ’20 XPro1595 UK Alzheimer’s Initiate Enrollment of Phase 1 Study - Q3’19 INKmune UK Ovarian Cancer Report Initial Phase 1 Data - 1H ’20 XPro1595 UK Alzheimer’s Early Data - Q1’20 INKmune UK Ovarian Cancer Initiate Phase 2 Study - 2H ’20 INB03 Australia/US Solid Tumors Initiate INB03 + CPI* Phase 2 Combination Study - 1H ’20 The Alzheimer Association believes in INMB In order to advance XPro1595 in the treatment of AD, INmune was recently awarded a $1 million grant from the Alzheimer’s Association. The grant will support a biomarker-directed Phase 1 clinical trial in 18 patients with mild-to-moderate AD. XPro1595 will be administered subcutaneously once a week for three months and biomarkers of inflammation will be assessed at 0, 6, and 12 weeks. This ringing endorsement from the Alzheimer Association should have potential investors sold on INMB's potential to help treat this dreaded disease that effects 5.8M patients in the U.S. alone. The Smart Money Is Buying Up Shares In INMB Insiders own 63% of the outstanding shares of INMB. Insiders have spent $770,000 buying up company shares in the past two months. An institutional investor recently raised its position in INmune Bio stock. BlackRock Inc. boosted its stake in INmune Bio Inc (NASDAQ:INMB) by 1,556.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,048 shares of the company’s stock after acquiring an additional 2,864 shares during the period. BlackRock Inc.’s holdings in INmune Bio were worth $29,000 at the end of the most recent reporting period. 0.36% of the stock is owned by hedge funds and other institutional investors. Major shareholder Mark William Lowdell purchased 2,918 shares of INmune Bio stock in a transaction that occurred on Wednesday, September 11th. The stock was acquired at an average cost of $6.23 per share, with a total value of $18,179.14. The Company has zero debt! The fact that insiders own 63% of the shares, has us bullish on INMB's growth potential. Who would know better if the Company was undervalued than those working within? Tiny Float = Big Move Potential The public float for INMB is just 3.58M A float that low is a rarity for companies listed on the NASDAQ. It also means the IMNB could moonshot if it were to see an increase in daily volume. In fact, the first time INMB broke over 100K in daily volume, its shares had their biggest single day move, climbing from $8.80 to $10.68, for a single day gain of over +21%! INMB Trades At $5.60 And Has A $19 Price Target Zacks Small-Cap Research recently initiated coverage of INmune Bio, Inc. (NASDAQ:INMB) with a $19 valuation. INmune is a biopharmaceutical company developing therapies that target the innate immune system to treat cancer. In contrast to the adaptive immune system, which relies upon a highly targeted response to specific antigens, the innate immune system is designed to deliver a non-specific response to abnormal cells or foreign antigens. The company targets myeloid derived suppressor cells (MDSC) and natural killer (NK) cells through its lead development products, INB03 and INKmune. INB03 is designed to inhibit soluble tumor necrosis factor (sTNF), a key signaling molecule for MDSC activation while INKmune provides the necessary priming signal to convert NK cells from a ‘resting’ to an ‘active’ state. In addition to the two cancer therapies, INmune is also developing XPro1595 (which has a similar MOA as INB03) as a treatment for mild to moderate Alzheimer’s Disease. Upcoming catalysts for the company include: INB03 – A Phase 1 monotherapy trial is currently underway. This trial will transition to a combination therapy clinical trial in the summer of 2019. A Phase 2 clinical trial testing INB03 with checkpoint inhibitors in patients who are resistant to checkpoint inhibitor therapy will initiate in 2020. XPro1595 – We anticipate a Phase 1 clinical trial in patients with Alzheimer’s disease will initiate in the summer of 2019. This study is supported by a $1 million grant from the Alzheimer’s Association. INKmune – A Phase 1/2 clinical trial will initiate later in 2019 in patients with relapsed/refractory ovarian cancer. With an upside of over +239%, now could be the perfect time to start building a position in INMB. Recent Developments CEO of INmune Bio Inc. Discusses Company Accomplishments at Nasdaq’s MarketSite and Announces Presentation at World Immunotherapy Congress Yesterday, the Company announced that RJ Tesi, M.D., Co-Founder and CEO will be featured in an interview with multimedia financial reporter, Jason Lin discussing the company’s accomplishments. The interview can be found by clicking here. “Nasdaq’s MarketSite is a premiere platform for INmune Bio to share our story with investors and to discuss recent developments in our programs for cancer, Alzheimer’s disease and nonalcoholic steatohepatitis (NASH) liver disease,” said Dr. Tesi. “We hope to continue reaching new milestones in the development of therapies that target the innate immune system.” INmune Bio has four drug development programs: two that are designed to treat cancer, INKmune™ and INB03 — with recently reported positive preliminary data from the Phase 1 trial in patients with advanced cancer; XPro1595 for the treatment of neuroinflammation and Alzheimer’s disease; and NeuLiv™ for the treatment of NASH. Additionally, CJ Barnum, Ph.D., Director of Neuroscience, will present on “Approaching Alzheimer’s disease as an immunological disease: role of biomarkers” at the World Immunotherapy Congress on Oct. 16 in Switzerland Technical Analysis We've done our very own chart analysis on INMB, and see the potential for a move of over 60%! Bollinger Bands Have Tightened Signaling a Comprehensive Move Imminent Sell Volume Declining Very Strong Reversal of the Lows Bullish H&S Forming RSI in Oversold Territory The stock has seen multiple bounces and reversals throughout its short history, which leads us to believe that now may be the perfect entry point for those looking to capitalize on INMB's next potential chart reversal. The Bottom-Line We don't think INMB will be trading under the radar for much longer. We love the CEO's vision for the future. With its low-float, INMB could see a huge run-up on volume. ZERO Debt and Heavy Insider Ownership have us bullish heading into the 2nd half of 2019. (*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.) Best Regards, *Past performance is not an indicator of future returns. The publishers of this report are not investment advisors and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. The publishers of this report have received compensation from a third party of USD $10,000 cash for a 1-day marketing contract for INMB. Never make investment decisions based on anything the publisher of this report says. This message is meant for informational and educational purposes only and does not provide investment advice.
NASDAQ:INMBLong
by RedHotStocks
INMB is our fresh Nasdaq Stock Alert set for huge reversal trade===================== INmune Bio Inc. (INMB) Alert Price: $8.82 Float: 2.82M Corporate Presentation Fact Sheet 12-Month Consensus Price Target: $13.00 (Maxim Group) Website | Recent News ======================== Members, July was one of our most profitable months of 2019. We delivered 6 solid winners in a row for a grand total of +270% in realistic gains! We now plan to kickoff the month of August with what could be one of our biggest long-term winners yet. Just like two of our most recent winners, the Company trades on the NASDAQ exchange and has tremendous growth potential. Please turn your immediate attention to INmune Bio Inc. (INMB). INMB is a clinical stage biotechnology company that is developing new immunotherapies that reprogram a patient’s innate immune system to allow the immune system to fight cancer and Alzheimer’s. INmune Bio Inc. is a developing novel therapies targeting distinct parts of a patient’s innate immune system to fight disease. Drug candidates, INKmune™ and INB03, may be used to treat cancer. XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease. INmune Bio’s product platforms utilize a precision therapy approach, promoting the body’s innate immune response to treat unsolved problems in medicine. INMB's therapies provide treatment for diseases that effect millions of patients each year. Alzheimer’s Disease – The Alzheimer’s disease therapeutics market will grow to be worth more than $12 billion annually by 2026. Cancer Residual Disease – About 1.7 million patients are affected by this every year, with nearly 610,000 patients dying as a result. Checkpoint Inhibitor Market – The global checkpoint inhibitor market will grow to be worth more than $40 billion annually by the year 2026. About INmune Bio, Inc. INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (NK) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid-derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com. INMB Pipeline INKmune-Cancer - in oncology patients that relapse, cells that are known to target residual cancer cells, fail to eliminate the remainder of the disease after treatment. INMB is working to keep this from happening with INKmune. INB03-Alzheimers - targets myeloid derived suppressor cells, or MDSC, believed to be the reason that many cancer patients do not respond to checkpoint inhibitor treatments. XPro1595-Cancer – is under development as a potential option for patients with Alzheimer’s disease, believed to be caused by neuroinflammation of brain cells. The company believes XPro1595 will inhibit neuroinflammation and the resultant cell death. INMB's Pipeline's Multi-Billion Dollar Market Opportunity • XPro1595 - Alzheimer’s/dementia market* – 5.8 M patients in US – 2019 est cost to care for US AD patients $280B • INKmune - Cancer residual disease market ** – 1,735,350 new cases and 609,640 people will die – Initial targets: Ovarian Cancer and High Risk MDS • INB03 - Resistance to Checkpoint Inhibitors market*** – CPI’s work 27% of patients. CPI 2025 est market size $56B – INB03 in combination with CPI’s should increase the number of patients sensitive to CPIs. – Initial targets: Melanoma and Renal Cell Cancer All three of the candidates in the company’s pipeline are either currently in Phase 1 clinical studies or are about to begin Phase 1 clinical studies in the near term. INB03 Australia Solid Tumors Initial Phase 1 Data Readout- Q3 ’19 INKmune UK Ovarian Cancer Initiate Enrollment of Phase 1/2 study - Q4 ’19 INB03 Australia Solid Tumors Initiate Combination Study, Additional Cohorts to Phase 1 Study- 1H ’20 XPro1595 UK Alzheimer’s Initiate Enrollment of Phase 1 Study - Q3’19 INKmune UK Ovarian Cancer Report Initial Phase 1 Data - 1H ’20 XPro1595 UK Alzheimer’s Early Data - Q1’20 INKmune UK Ovarian Cancer Initiate Phase 2 Study - 2H ’20 INB03 Australia/US Solid Tumors Initiate INB03 + CPI* Phase 2 Combination Study - 1H ’20 The Alzheimer Association believes in IMNB In order to advance XPro1595 in the treatment of AD, INmune was recently awarded a $1 million grant from the Alzheimer’s Association. The grant will support a biomarker-directed Phase 1 clinical trial in 18 patients with mild-to-moderate AD. XPro1595 will be administered subcutaneously once a week for three months and biomarkers of inflammation will be assessed at 0, 6, and 12 weeks. This ringing endorsement from the Alzheimer Association should have potential investors sold on IMNB's potential to help treat this dreaded disease that effects 5.8M patients in the U.S. alone. The Smart Money Is Buying Up Shares In IMNB Insiders own 63% of the outstanding shares of INMB. Insiders have spent $770,000 buying up company shares in the past two months. The Company has zero debt! The fact that insiders own 63% of the shares, has us bullish on INMB's growth potential. Who would know better if the Company was undervalued than those working within. Tiny Float = Big Move Potential The public float for IMNB is just 2.98M A float that low is a rarity for companies listed on the NASDAQ. It also means the IMNB could moonshot if it were to see an increase in daily volume. In fact, the first time IMNB broke over 100K in daily volume, its shares had their biggest single day move, climbing from $8.80 to $10.68, for a single day gain of over +21%! INMB Trades Under $9 And Has A $13 Price Target In March, Maxim Group launched coverage of INMB with a “buy” rating and $13 price target. Analyst Jason McCarthy stated that INB03, a selective TNF inhibitor downregulates the immunosuppressive factors found in the tumor microenvironment, turning cold tumors hot. An open-label Phase 1 study is ongoing, with data expected in the second quarter of 2019. He said XPro1595 selectively targets the soluble form of TNF and may inhibit activated microglia, a type of innate immune cell, representing a differentiated approach, compared with targeting beta amyloid or tau. XPro1595’s preclinical data has been positive, he said, and a Phase 1 study is scheduled to start in the second quarter of 2019. Also initiating in the second quarter of 2019 is a Phase 1/2 study of INKmune, a modified tumor cell line that primes existing natural killer cells. “Innate immunity is a space that continues to evolve and rise behind CAR-T and checkpoints (both target adaptive immunity), with multiple players in the space, including big pharma/biotech,” Mr. McCarthy said. “INmune's programs should report data in 2019 providing catalysts for the stock to support a higher valuation,” he added. With an upside of over +47%, now could be the perfect time to start building a position in INMB. Recent Developments INmune Bio Co-Founder and CEO RJ Tesi Presents at Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit This week, RJ Tesi, M.D., co-founder and CEO, will present at the Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit. We will be keeping a close eye on this, as any data that comes out could serve as a strong bullish catalyst for INMB's share price. Technical Analysis We've done our very own chart analysis on INMB, and we the potential for a move of over 21%! The stock has seen multiple bounces and reversals from these levels, which leads us to believe that now may be the perfect entry point for those looking to capitalize on INMB's next potential chart reversal. The Bottom-Line We don't think INMB will be trading under the radar for much longer. Any positive data released by the Company could grab the attention of Wall St. With its low-float, INMB could see a huge run-up. ZERO Debt and Heavy Insider Ownership have us bullish heading into the 2nd half of 2019. (*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.) Best Regards, DISCLAIMER This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future. MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by World Wide Holdings dba Invictus Resources for a 1-day investor relations advertising marketing campaign w/ 1500 TradingView™ views for INMB. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
NASDAQ:INMBLong
by CryptoCurrencyAlerts
INMB is our fresh Nasdaq Stock Alert set for huge reversal trade===================== INmune Bio Inc. (INMB) Alert Price: $8.82 Float: 2.82M Corporate Presentation Fact Sheet 12-Month Consensus Price Target: $13.00 (Maxim Group) Website | Recent News ======================== Members, July was one of our most profitable months of 2019. We delivered 6 solid winners in a row for a grand total of +270% in realistic gains! We now plan to kickoff the month of August with what could be one of our biggest long-term winners yet. Just like two of our most recent winners, the Company trades on the NASDAQ exchange and has tremendous growth potential. Please turn your immediate attention to INmune Bio Inc. (INMB). INMB is a clinical stage biotechnology company that is developing new immunotherapies that reprogram a patient’s innate immune system to allow the immune system to fight cancer and Alzheimer’s. INmune Bio Inc. is a developing novel therapies targeting distinct parts of a patient’s innate immune system to fight disease. Drug candidates, INKmune™ and INB03, may be used to treat cancer. XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease. INmune Bio’s product platforms utilize a precision therapy approach, promoting the body’s innate immune response to treat unsolved problems in medicine. INMB's therapies provide treatment for diseases that effect millions of patients each year. Alzheimer’s Disease – The Alzheimer’s disease therapeutics market will grow to be worth more than $12 billion annually by 2026. Cancer Residual Disease – About 1.7 million patients are affected by this every year, with nearly 610,000 patients dying as a result. Checkpoint Inhibitor Market – The global checkpoint inhibitor market will grow to be worth more than $40 billion annually by the year 2026. About INmune Bio, Inc. INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (NK) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid-derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com. INMB Pipeline INKmune-Cancer - in oncology patients that relapse, cells that are known to target residual cancer cells, fail to eliminate the remainder of the disease after treatment. INMB is working to keep this from happening with INKmune. INB03-Alzheimers - targets myeloid derived suppressor cells, or MDSC, believed to be the reason that many cancer patients do not respond to checkpoint inhibitor treatments. XPro1595-Cancer – is under development as a potential option for patients with Alzheimer’s disease, believed to be caused by neuroinflammation of brain cells. The company believes XPro1595 will inhibit neuroinflammation and the resultant cell death. INMB's Pipeline's Multi-Billion Dollar Market Opportunity • XPro1595 - Alzheimer’s/dementia market* – 5.8 M patients in US – 2019 est cost to care for US AD patients $280B • INKmune - Cancer residual disease market ** – 1,735,350 new cases and 609,640 people will die – Initial targets: Ovarian Cancer and High Risk MDS • INB03 - Resistance to Checkpoint Inhibitors market*** – CPI’s work 27% of patients. CPI 2025 est market size $56B – INB03 in combination with CPI’s should increase the number of patients sensitive to CPIs. – Initial targets: Melanoma and Renal Cell Cancer All three of the candidates in the company’s pipeline are either currently in Phase 1 clinical studies or are about to begin Phase 1 clinical studies in the near term. INB03 Australia Solid Tumors Initial Phase 1 Data Readout- Q3 ’19 INKmune UK Ovarian Cancer Initiate Enrollment of Phase 1/2 study - Q4 ’19 INB03 Australia Solid Tumors Initiate Combination Study, Additional Cohorts to Phase 1 Study- 1H ’20 XPro1595 UK Alzheimer’s Initiate Enrollment of Phase 1 Study - Q3’19 INKmune UK Ovarian Cancer Report Initial Phase 1 Data - 1H ’20 XPro1595 UK Alzheimer’s Early Data - Q1’20 INKmune UK Ovarian Cancer Initiate Phase 2 Study - 2H ’20 INB03 Australia/US Solid Tumors Initiate INB03 + CPI* Phase 2 Combination Study - 1H ’20 The Alzheimer Association believes in IMNB In order to advance XPro1595 in the treatment of AD, INmune was recently awarded a $1 million grant from the Alzheimer’s Association. The grant will support a biomarker-directed Phase 1 clinical trial in 18 patients with mild-to-moderate AD. XPro1595 will be administered subcutaneously once a week for three months and biomarkers of inflammation will be assessed at 0, 6, and 12 weeks. This ringing endorsement from the Alzheimer Association should have potential investors sold on IMNB's potential to help treat this dreaded disease that effects 5.8M patients in the U.S. alone. The Smart Money Is Buying Up Shares In IMNB Insiders own 63% of the outstanding shares of INMB. Insiders have spent $770,000 buying up company shares in the past two months. The Company has zero debt! The fact that insiders own 63% of the shares, has us bullish on INMB's growth potential. Who would know better if the Company was undervalued than those working within. Tiny Float = Big Move Potential The public float for IMNB is just 2.98M A float that low is a rarity for companies listed on the NASDAQ. It also means the IMNB could moonshot if it were to see an increase in daily volume. In fact, the first time IMNB broke over 100K in daily volume, its shares had their biggest single day move, climbing from $8.80 to $10.68, for a single day gain of over +21%! INMB Trades Under $9 And Has A $13 Price Target In March, Maxim Group launched coverage of INMB with a “buy” rating and $13 price target. Analyst Jason McCarthy stated that INB03, a selective TNF inhibitor downregulates the immunosuppressive factors found in the tumor microenvironment, turning cold tumors hot. An open-label Phase 1 study is ongoing, with data expected in the second quarter of 2019. He said XPro1595 selectively targets the soluble form of TNF and may inhibit activated microglia, a type of innate immune cell, representing a differentiated approach, compared with targeting beta amyloid or tau. XPro1595’s preclinical data has been positive, he said, and a Phase 1 study is scheduled to start in the second quarter of 2019. Also initiating in the second quarter of 2019 is a Phase 1/2 study of INKmune, a modified tumor cell line that primes existing natural killer cells. “Innate immunity is a space that continues to evolve and rise behind CAR-T and checkpoints (both target adaptive immunity), with multiple players in the space, including big pharma/biotech,” Mr. McCarthy said. “INmune's programs should report data in 2019 providing catalysts for the stock to support a higher valuation,” he added. With an upside of over +47%, now could be the perfect time to start building a position in INMB. Recent Developments INmune Bio Co-Founder and CEO RJ Tesi Presents at Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit This week, RJ Tesi, M.D., co-founder and CEO, will present at the Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit. We will be keeping a close eye on this, as any data that comes out could serve as a strong bullish catalyst for INMB's share price. Technical Analysis We've done our very own chart analysis on INMB, and we the potential for a move of over 21%! The stock has seen multiple bounces and reversals from these levels, which leads us to believe that now may be the perfect entry point for those looking to capitalize on INMB's next potential chart reversal. The Bottom-Line We don't think INMB will be trading under the radar for much longer. Any positive data released by the Company could grab the attention of Wall St. With its low-float, INMB could see a huge run-up. ZERO Debt and Heavy Insider Ownership have us bullish heading into the 2nd half of 2019. (*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.) DISCLAIMER This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future. MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by World Wide Holdings dba Invictus Resources for a 1-day investor relations advertising marketing campaign w/ 1500 TradingView™ views for INMB. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
NASDAQ:INMBLong
by DEXWireNews
INMB is our fresh Nasdaq Stock Alert set for huge reversal trade===================== INmune Bio Inc. (INMB) Alert Price: $8.82 Float: 2.82M Corporate Presentation Fact Sheet 12-Month Consensus Price Target: $13.00 (Maxim Group) Website | Recent News ======================== Members, July was one of our most profitable months of 2019. We delivered 6 solid winners in a row for a grand total of +270% in realistic gains! We now plan to kickoff the month of August with what could be one of our biggest long-term winners yet. Just like two of our most recent winners, the Company trades on the NASDAQ exchange and has tremendous growth potential. Please turn your immediate attention to INmune Bio Inc. (INMB). INMB is a clinical stage biotechnology company that is developing new immunotherapies that reprogram a patient’s innate immune system to allow the immune system to fight cancer and Alzheimer’s. INmune Bio Inc. is a developing novel therapies targeting distinct parts of a patient’s innate immune system to fight disease. Drug candidates, INKmune™ and INB03, may be used to treat cancer. XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease. INmune Bio’s product platforms utilize a precision therapy approach, promoting the body’s innate immune response to treat unsolved problems in medicine. INMB's therapies provide treatment for diseases that effect millions of patients each year. Alzheimer’s Disease – The Alzheimer’s disease therapeutics market will grow to be worth more than $12 billion annually by 2026. Cancer Residual Disease – About 1.7 million patients are affected by this every year, with nearly 610,000 patients dying as a result. Checkpoint Inhibitor Market – The global checkpoint inhibitor market will grow to be worth more than $40 billion annually by the year 2026. About INmune Bio, Inc. INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (NK) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid-derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com. INMB Pipeline INKmune-Cancer - in oncology patients that relapse, cells that are known to target residual cancer cells, fail to eliminate the remainder of the disease after treatment. INMB is working to keep this from happening with INKmune. INB03-Alzheimers - targets myeloid derived suppressor cells, or MDSC, believed to be the reason that many cancer patients do not respond to checkpoint inhibitor treatments. XPro1595-Cancer – is under development as a potential option for patients with Alzheimer’s disease, believed to be caused by neuroinflammation of brain cells. The company believes XPro1595 will inhibit neuroinflammation and the resultant cell death. INMB's Pipeline's Multi-Billion Dollar Market Opportunity • XPro1595 - Alzheimer’s/dementia market* – 5.8 M patients in US – 2019 est cost to care for US AD patients $280B • INKmune - Cancer residual disease market ** – 1,735,350 new cases and 609,640 people will die – Initial targets: Ovarian Cancer and High Risk MDS • INB03 - Resistance to Checkpoint Inhibitors market*** – CPI’s work 27% of patients. CPI 2025 est market size $56B – INB03 in combination with CPI’s should increase the number of patients sensitive to CPIs. – Initial targets: Melanoma and Renal Cell Cancer All three of the candidates in the company’s pipeline are either currently in Phase 1 clinical studies or are about to begin Phase 1 clinical studies in the near term. INB03 Australia Solid Tumors Initial Phase 1 Data Readout- Q3 ’19 INKmune UK Ovarian Cancer Initiate Enrollment of Phase 1/2 study - Q4 ’19 INB03 Australia Solid Tumors Initiate Combination Study, Additional Cohorts to Phase 1 Study- 1H ’20 XPro1595 UK Alzheimer’s Initiate Enrollment of Phase 1 Study - Q3’19 INKmune UK Ovarian Cancer Report Initial Phase 1 Data - 1H ’20 XPro1595 UK Alzheimer’s Early Data - Q1’20 INKmune UK Ovarian Cancer Initiate Phase 2 Study - 2H ’20 INB03 Australia/US Solid Tumors Initiate INB03 + CPI* Phase 2 Combination Study - 1H ’20 The Alzheimer Association believes in IMNB In order to advance XPro1595 in the treatment of AD, INmune was recently awarded a $1 million grant from the Alzheimer’s Association. The grant will support a biomarker-directed Phase 1 clinical trial in 18 patients with mild-to-moderate AD. XPro1595 will be administered subcutaneously once a week for three months and biomarkers of inflammation will be assessed at 0, 6, and 12 weeks. This ringing endorsement from the Alzheimer Association should have potential investors sold on IMNB's potential to help treat this dreaded disease that effects 5.8M patients in the U.S. alone. The Smart Money Is Buying Up Shares In IMNB Insiders own 63% of the outstanding shares of INMB. Insiders have spent $770,000 buying up company shares in the past two months. The Company has zero debt! The fact that insiders own 63% of the shares, has us bullish on INMB's growth potential. Who would know better if the Company was undervalued than those working within. Tiny Float = Big Move Potential The public float for IMNB is just 2.98M A float that low is a rarity for companies listed on the NASDAQ. It also means the IMNB could moonshot if it were to see an increase in daily volume. In fact, the first time IMNB broke over 100K in daily volume, its shares had their biggest single day move, climbing from $8.80 to $10.68, for a single day gain of over +21%! INMB Trades Under $9 And Has A $13 Price Target In March, Maxim Group launched coverage of INMB with a “buy” rating and $13 price target. Analyst Jason McCarthy stated that INB03, a selective TNF inhibitor downregulates the immunosuppressive factors found in the tumor microenvironment, turning cold tumors hot. An open-label Phase 1 study is ongoing, with data expected in the second quarter of 2019. He said XPro1595 selectively targets the soluble form of TNF and may inhibit activated microglia, a type of innate immune cell, representing a differentiated approach, compared with targeting beta amyloid or tau. XPro1595’s preclinical data has been positive, he said, and a Phase 1 study is scheduled to start in the second quarter of 2019. Also initiating in the second quarter of 2019 is a Phase 1/2 study of INKmune, a modified tumor cell line that primes existing natural killer cells. “Innate immunity is a space that continues to evolve and rise behind CAR-T and checkpoints (both target adaptive immunity), with multiple players in the space, including big pharma/biotech,” Mr. McCarthy said. “INmune's programs should report data in 2019 providing catalysts for the stock to support a higher valuation,” he added. With an upside of over +47%, now could be the perfect time to start building a position in INMB. Recent Developments INmune Bio Co-Founder and CEO RJ Tesi Presents at Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit This week, RJ Tesi, M.D., co-founder and CEO, will present at the Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit. We will be keeping a close eye on this, as any data that comes out could serve as a strong bullish catalyst for INMB's share price. Technical Analysis We've done our very own chart analysis on INMB, and we the potential for a move of over 21%! The stock has seen multiple bounces and reversals from these levels, which leads us to believe that now may be the perfect entry point for those looking to capitalize on INMB's next potential chart reversal. The Bottom-Line We don't think INMB will be trading under the radar for much longer. Any positive data released by the Company could grab the attention of Wall St. With its low-float, INMB could see a huge run-up. ZERO Debt and Heavy Insider Ownership have us bullish heading into the 2nd half of 2019. (*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.) DISCLAIMER This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future. MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by World Wide Holdings dba Invictus Resources for a 1-day investor relations advertising marketing campaign w/ 1500 TradingView™ views for INMB. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
NASDAQ:INMBLong
by RedHotStocks